Back to results
US 10,238,742 B2Granted
Cell penetrating nucleolytic antibody based cancer therapy
AssigneesYale University, The United States of America as represented by the Department of Veterans Affairs
InventorsJames E. Hansen, Richard H. Weisbart, Philip W. Noble
Life of this patent
Estimating the term…
Abstract
Cancer cells with defects in DNA repair are highly susceptible to DNA-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A sub-set of autoantibodies having nucleolytic activity are capable of nuclear penetration. These antibodies can be used as therapeutic agents targeted towards DNA repair-deficient malignancies.
Claims12
A pharmaceutical composition comprising
- a) a cell-penetrating, nucleolytic antibody, or antigen binding fragment thereof, comprising:
- a heavy chain variable region comprising respectively the first, second, and third complementarity determining regions (CDRs) of SEQ ID NO:5 or humanized variants thereof, and
- a light chain variable region comprising respectively the first, second, and third CDRs of SEQ ID NO:1 or humanized variants thereof,
- in a unit dosage between about 0.01 and about 100 mg/kg body weight of a human;
- and
- b) a pharmaceutically acceptable excipient for injection.
3 more elements
Dependencies are inferred from the claim text.